Aminata Dieng
Medical · Staten Island, NYNPI 1881081784
Payments from drug & device makers
Across 130 payments — averaging $27.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$388
- AstraZeneca$316
- Amgen$238
- Merck$225
- Bristol Myers Squibb$202
- Johnson & Johnson$198
- plus $2K from 30 others
What the payments were for
- Food & beverage$2,74377%
- Education$81523%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 13 | $388 |
| AstraZeneca | 10 | $316 |
| Amgen | 6 | $238 |
| Merck | 10 | $225 |
| Bristol Myers Squibb | 8 | $202 |
| Johnson & Johnson(2 entities) | 5 | $198 |
| Lilly USA, LLC | 5 | $180 |
| Eisai Inc. | 8 | $167 |
| Incyte Corporation | 3 | $150 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $132 |
| E.r. Squibb & Sons, L.L.C. | 6 | $123 |
| Astellas Pharma US Inc | 1 | $100 |
| Aurinia Pharma U.S., Inc. | 5 | $99 |
| AbbVie | 1 | $99 |
| Fresenius USA Marketing, Inc. | 5 | $99 |
| Pfizer | 4 | $81 |
| Travere Therapeutics, Inc. | 4 | $78 |
| Daiichi Sankyo Inc. | 3 | $74 |
| Calliditas Therapeutics US Inc. | 3 | $65 |
| OPKO Pharmaceuticals, LLC | 3 | $61 |
| Akebia Therapeutics Inc | 2 | $51 |
| Myovant Sciences Inc. | 2 | $49 |
| Novocure Inc. | 4 | $46 |
| Vifor Pharma, Inc. | 2 | $43 |
| Ardelyx, Inc. | 2 | $40 |
| Bayer | 1 | $26 |
| Boehringer Ingelheim | 1 | $26 |
| Cormedix Inc. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Puma Biotechnology, Inc. | 1 | $23 |
| Deciphera Pharmaceuticals Inc. | 1 | $23 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $23 |
| GSK | 1 | $23 |
| Mozarc Medical US LLC | 1 | $20 |
| Array Biopharma Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,558 in reported general payments places this provider in the 85th percentile of 2,395 medical providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 14 | $21,180 |
| Sevelamer Carbonate | 15 | $2,005 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $99 | $21,18014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,395 medical providers in New York.
Other medical in Staten Island
- Rebecca EllwoodAlbany$565K
- Denisse SerranoCortlandt Manor$255K
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Carl ClarkeBrooklyn$116K
- Maureen ThyneNew York$109K
- Gina FriesRochester$106K
- Ilse StraussSmithtown$87K
- Helen AdamsNew York$87K
- Hailey BrickmanNew York$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.